MetrioPharm Investor Relations News QIV 2017

End-of-the-year Review by Dr. Wolfgang Brysch, CEO of MetrioPharm AG

Dear shareholders,

The year 2017 was literally a jubilee year for MetrioPharm AG. We even had two occasions to celebrate:

In March, we received the results of our Phase IIa clinical trial in which we evaluated the safety and tolerability of prolonged, continuous administration of MP1032 in patients. In addition, we had hoped for first indications of the therapeutic efficacy in chronic autoimmune diseases. Psoriasis was chosen as a model disease (proof-of-principle). We are very pleased to have achieved both of these objectives and have thus successfully overcome one of the most important hurdles to market approval of MP1032.

In September, employees and founders of MetrioPharm AG jointly celebrated. It was exactly ten years ago that we moved into our first offices with a small, highly motivated team and began to develop promising drug candidates. We have left these first offices in the meantime, over the years they have become too small for our growing number of employees. The core team of that time still works with us, highly motivated until today.

We take this tenth anniversary as an opportunity to launch a new project: the MetrioPharm Blog. In the future, we will be able to inform our shareholders and the interested public about current projects as well as the background of our work at MetrioPharm AG. In January, you will hear more about this project from our IR department, and I will tell you just so much about it: I am looking forward to the new concept and to contributing right from the start.

Finally, the outlook for 2018: The next phase II clinical trial, in which we will test different doses of MP1032 over a longer period of time, will begin in the spring. The first psoriasis patients are expected to be included in this study in March. The new year looks to be an exciting one and I am looking forward to continuing our successful journey together!

On behalf of the entire team and management of MetrioPharm AG, I wish you a Merry Christmas and relaxing holidays.

Yours sincerely,

Dr. Wolfgang Brysch
Chief Executive Officer

MetrioPharm AG at the Bio-Europe 2017 in Berlin

Over 4000 attendees from 2000 companies attended the Bio-Europe 2017 in Berlin. From November 6 to 8, Dr. Wolfgang Brysch, CEO, and Felix Edler, Business Development, presented MetrioPharm's phase IIa results and preclinical data to potential pharma-partners and investors in numerous one-to-one meetings. First follow-up dates have already been agreed on.

MetrioPharm AG at the German Equity Forum 2017

Following last year's successful start, MetrioPharm AG took part in the German Equity Forum as a member of the Deutsche Börse Venture Network for the first time this year. During the two-day stay, numerous one-on-one meetings were held and new contacts were made. In addition, Eva Brysch, Investor Relations, presented MetrioPharm AG to interested investors at the Venture Stage on November 29, 2017.

Investor Talks with MetrioPharm AG in New York

On December 14, 2017, Dr. Wolfgang Brysch, CEO, presented MetrioPharm AG to potential investors in New York during the Investor Talks. The Investor Talks were organized by Deutsche Börse Venture Network in cooperation with Edison to give European unlisted companies the opportunity to present themselves to an interested US public and to use the framework of Investor Talks for networking.

Corporate Calendar of MetrioPharm AG in QI 2018

January, 08-11, 2018: J.P. Morgan Healthcare Conference, San Francisco, USA

The J. P. Morgan Healthcare Conference has established itself as one of the leading conferences for the healthcare sector and numerous investors and pharmaceutical companies from around the world will travel to San Francisco in the second week of January. MetrioPharm AG, represented by Dr. Wolfgang Brysch, CEO, and Felix Edler, Business Development, will use this opportunity to intensify discussions with potential business and licensing partners.

If there will be further dates for the first quarter, you can find out more at any time on our website at www.metriopharm.com

Dr. Sara Schumann New at MetrioPharm

Since October 2017, Dr. Sara Schumann has been taking over the Research & Development division as project manager. Dr. Schumann studied biochemistry at the University of Potsdam and then obtained her doctorate at the German Institute for Nutritional Research (Deutsches Institut für Ernährungsforschung) in the field of chronic inflammatory bowel diseases. During her scientific career, Dr. Schumann has successfully led various projects and published numerous publications in renowned journals. With this experience, she now occupies the interface between our preclinical research partners and MetrioPharm AG.

Your contact at MetrioPharm is:

Download